Mark Steedman | Team | Hambro Perks

Mark Steedman
Special Opportunities Fund

Mark is a Portfolio Director working with companies in the HP Special Opportunities Fund. Mark is a Life Sciences and Healthcare expert with a background that spans research, finance and operations.

Prior to joining the team, Mark was COO of a portfolio company, BrYet Ltd, commercialising a novel cancer therapy. Before this, Mark was responsible for research and insight in the Life Sciences sector at Deloitte. He also held a number of research and policy roles at Imperial College, UCSF and University of Washington.

Mark holds a Bachelor of Science degree from the University of Washington and a PhD in Bioengineering from UCSF.

Back to People

Hambro Perks Limited and members of the Hambro Perks group of companies (together, the “HP Group”) include Hambro Perks Asset Management Limited (“HPAM Ltd”) and Hambro Perks Advisory LLP (“HPA LLP”).

HPAM Ltd is a non-cellular company incorporated in Guernsey with company number 64127 and registered office at PO Box 286, 2nd Floor, Trafalgar Court, Les Banques, St Peter Port, Guernsey, GY1 4LY. HPAM Ltd is licensed under the Protection of Investors (Bailiwick of Guernsey) Law, 1987, by the Guernsey Financial Services Commission with reference number 2293289.

HPA LLP is a Limited Liability Partnership registered in England with company number OC419104, with registered office at 111 Buckingham Palace Road, London SW1W 0SR. HPA LLP is an appointed representative of Alternative St James LLP which is authorised and regulated by the Financial Conduct Authority with FCA number 430914. HPA LLP’s FCA number is 791891.